Iovance: Strong Melanoma Sales Offset by Lung Data Setback
Read source articleWhat happened
Iovance's core melanoma franchise delivered its best quarter with Amtagvi revenue of $101.6 million, up 77% sequentially, and operating cash burn nearly eliminated at -$4.47 million, validating the commercial ramp that was previously uncertain. However, the stock fell 47.6% after a lung cancer update showed an 8.51% response rate outside a post-hoc subgroup, below the 12.8% benchmark for docetaxel, undermining the pipeline expansion story. The Seeking Alpha author argues the selloff was overdone, citing a sum-of-the-parts fair value of $8.86 in the base case and $13.32 in a bull case, versus the current price of $7.76. The earlier DeepValue report had rated the stock a WAIT at $4.30, concerned about cash burn, gross margin, and execution, but those concerns have partly been alleviated by the latest quarter. Still, the lung data disappointment reduces the probability assigned to pipeline upside, and the post-hoc nature of the subgroup raises questions about the reliability of the positive spin.
Implication
The core melanoma business appears to be reaching a self-sustaining trajectory with near-breakeven cash flow, which reduces dilution risk and supports a re-rating relative to the prior WAIT stance. However, the lung cancer update was a significant setback, with low response rates outside cherry-picked subgroups, reducing the probability that Amtagvi expands beyond melanoma. At $7.76, the stock trades above the earlier base-case fair value of $4.90, but below the article's sum-of-the-parts value of $8.86, suggesting a modest margin of safety only if the lung program retains some value. Investors should demand clear evidence that the strong Amtagvi revenue growth is sustainable and not inflated by Proleukin stocking, and that the lung trial's pre-specified subgroup (if any) truly represents a viable market. Until the company provides cleaner data and confirms the melanoma trajectory, the stock remains a hold rather than a buy, with key catalysts being further revenue quarters and regulatory updates on the lung program.
Thesis delta
The core investment thesis has strengthened as Amtagvi revenue growth and near-breakeven cash burn alleviate prior execution concerns, shifting the outlook from WAIT to a more balanced view. However, the disappointing lung cancer data reduces the pipeline expansion thesis, and the post-hoc subgroup analysis raises credibility concerns. Net, Iovance is now a 'show-me' story with improved fundamentals but a lower ceiling for near-term upside.
Confidence
Moderate